Hvivo, a leading clinical research organisation headquartered in Great Britain, specialises in the development and testing of innovative therapies and vaccines. Founded in 2006, the company has established itself as a pioneer in the field of human challenge studies, providing unique insights into infectious diseases. With operational hubs across Europe and North America, Hvivo offers a range of services, including clinical trial management and laboratory services, that are tailored to meet the needs of biopharmaceutical clients. Notable for its state-of-the-art facilities and expertise in respiratory and viral infections, Hvivo has achieved significant milestones, including partnerships with major pharmaceutical companies. Its commitment to advancing medical research positions Hvivo as a trusted partner in the industry, driving forward the development of life-saving treatments and vaccines.
How does Hvivo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hvivo's score of 46 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, hVIVO reported total carbon emissions of approximately 192,400 kg CO2e. This figure includes 14,900 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and 162,800 kg CO2e from Scope 2 emissions related to purchased electricity. Additionally, Scope 3 emissions, which encompass business travel, accounted for about 14,700 kg CO2e. Comparatively, in 2023, hVIVO's total emissions were about 148,100 kg CO2e, with Scope 1 emissions at 12,600 kg CO2e, Scope 2 emissions at 78,200 kg CO2e, and Scope 3 emissions from business travel reaching approximately 57,300 kg CO2e. The 2022 data shows a total of around 104,300 kg CO2e, with Scope 1 emissions at 63,800 kg CO2e, Scope 2 at 12,900 kg CO2e, and Scope 3 at 27,600 kg CO2e. Despite these emissions figures, hVIVO has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company operates independently without cascading emissions data from a parent organization, ensuring that its reported figures reflect its own operational impact. hVIVO's commitment to addressing climate change remains a focus, although specific strategies or pledges have not been detailed in the available data.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 63,800 | 00,000 | 00,000 |
| Scope 2 | 12,900 | 00,000 | 000,000 |
| Scope 3 | 27,600 | 00,000 | 00,000 |
Hvivo's Scope 3 emissions, which decreased by 74% last year and decreased by approximately 47% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 8% of total emissions under the GHG Protocol, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hvivo has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
